



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To,

Date: 28.06.2021

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 28.06.2021

Ref: Our Company's letter dated 16.06.2021

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Monday, 28.06.2021 at 4:00 p.m. at the registered office of the company the following were considered and approved:

1. Audited financial results for the quarter and year ended 31.03.2021. **(Enclosed)**
2. Auditors Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2021. **(Enclosed)**

The meeting concluded at 8:45 p.m.

This is for the information and records of the Exchange, please.

Thanking you.


Yours sincerely,
For Concord Drugs Limited

S. Nagi Reddy

S. Nagi Reddy
Chairman & Whole time Director
DIN: 01764665



Encl: as above



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2021

[Rs. in Lakhs]

Particulars	Quarterly ended			Year ended	
	31-Mar-21 (Audited)	31-Dec-20 (Unaudited)	31-Mar-20 (Audited)	31-Mar-21 (Audited)	31-Mar-20 (Audited)
I Revenue from Operations					
a. Net sales from Operations	834.632	824.07	1,302.82	5,135.702	5,133.89
b. Other Operating Income	2.152	0.67	4.55	9.458	12.01
II Other Income					
III Total Revenue (I+II)	836.784	824.74	1,307.373	5,145.160	5,145.89
IV Expenses					
a. Cost of Material Consumed	552.782	614.42	1,116.82	4,049.154	4,206.02
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	42.560	2.66	20.65	168.667	51.72
c. Employees Benefit Expenses	92.290	95.17	84.78	375.547	350.72
d. Finance Costs	27.486	21.74	26.96	142.027	154.37
e. Depreciation and Amortisation expense	33.223	38.75	36.28	136.534	146.39
f. Other expenses	74.356	46.67	48.19	220.350	191.03
Total Expenses	822.697	819.40	1,292.38	5,092.278	5,100.25
Profit/ (Loss) before Exceptional item and tax (III-IV)	14.087	5.34	14.99	52.882	45.65
V Exceptional Items	23.981	352.34	-	376.317	-
VI Profit/ (Loss) before tax (IV+V)	38.068	357.67	14.99	429.199	45.65
VII Tax Expense:					
a. Current tax	4.501	87.83	3.28	101.032	12.82
b. Deferred tax charge/credit	0.155	39.77	3.03	47.067	11.91
IX Profit/ (Loss) for the period (VII-VIII)	33.567	269.84	11.72	328.17	32.83
X Other Comprehensive Income					
Items that will not be reclassified to profit or loss	-	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	33.567	269.84	11.72	328.17	32.826
XI Paid-up equity share capital (Face value of the share- Rs. 10 each)	874.375	874.38	874.38	874.375	874.375
XII Earnings per share (of Rs. 10 each)	1,802.249	1,464.77	1,474.08	1,802.249	1,474.082
XIII a. Basic (in Rs)	0.38	3.09	0.13	3.75	0.38
b. Diluted (in Rs)	0.38	3.09	0.13	3.75	0.38

Notes:


- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 28 th June ,2021
- The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
Note: The figures for the qtrr ended March 31, 2020 are balancing figures between the Audited figures of the full financial year ended 31, March 2021 & the published year to date figures upto 9 months ended Dec 31,2020
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in

Place: Hyderabad
Date: 28.06.2021



By Order of the Board
For Concord Drugs Limited

S. N. R. Reddy
Managing Director
DIN: 01764665



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

Concord Drugs Limited, Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana			
Balance sheet as at 31st March, 2021		Rs in Lakhs	
Particulars	Note	As At March 31, 2021	As At March 31, 2020
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	1,319.15	973.86
(b) Capital Work-in Progress	3	-0.00	99.77
(b) Investment property	3	63.95	78.60
Financial assets			
(a) Loans & Advances	5	2.64	53.62
Other Non current assets	4	1.44	39.29
Total Non - Current Assets		1,387.17	1,245.14
Current Assets			
Inventories	7	1,187.18	1,643.13
Financial assets			
(a) Investments			
(b) Trade receivables	6	2,072.80	2,544.60
(c) Cash and cash equivalents	8	3.55	1.21
(d) Bank balances other than (c) above	8	2.10	2.59
(e) Other Current Financial Assets	9	4.42	4.13
Other current assets	10	331.04	360.75
Total Current assets		3,601.10	4,556.40
Total Assets		4,988.27	5,801.55
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	874.38	874.38
Other equity	12	1,802.25	1,474.08
Total Equity		2,676.62	2,348.46
Non-current liabilities			
Financial Liabilities			
(a) Borrowings	13	60.30	87.72
(b) Trade payables			
Deferred tax liabilities, net	14	67.67	13.70
Provisions	15	208.38	208.38
Government Grants	13	36.92	45.53
Total Non-current liabilities		373.27	355.34
Current liabilities			
Financial liabilities			
(a) Borrowings	16	1,237.02	869.10
(b) Trade payables	17	314.77	1,279.62
(c) Other Current financial liabilities	18		
Current tax liabilities, net	15	47.07	11.91
Other current liabilities	19	339.52	937.13
Total Current liabilities		1,938.38	3,097.75
Total liabilities		2,311.65	3,453.09
Total Equity and liabilities		4,988.27	5,801.55
			0.00

Corporate information and significant accounting policies

1 & 2

For N.G Rao and Associates
Chartered Accountants
FRN- 009399S


SD/-
G. Nageswara Rao
Partner
Mno-207300
Place: Hyderabad
Date: 28.06.2021



For and on behalf of the Board of Directors of
Concord Drugs Limited

S. Nagi Reddy
Managing Director
DIN:01764665

Koni Reddy Seelam
Executive Director
DIN: 02829319



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana			
Statement of Cash flow for the year ended 31st March, 2021		Rs in Lakhs	
Particulars	As at March 31, 2021	As at March 31, 2020	
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit Before Tax	429.20		45.65
<i>Adjustments for :</i>			
<i>Profit on sale of ASSETS</i>			
Depreciation and amortisation expense	136.53		146.39
Finance costs	124.53		144.60
Interest income	(0.81)		(0.80)
Provision for Gratuity			-
Operating profit before working capital changes	689.46		335.84
<i>Changes in working capital: (Refer Note 40)</i>			
<i>Adjustments for (increase) / decrease in operating assets:</i>			
Financial Assets			
Trade receivables	471.79	2,298.87	
Loans and Advances	50.98	(3.60)	
Other Non Current assets	37.85	(0.03)	
Inventories	455.94	221.03	
Other Current assets	29.71	(117.22)	
Other bank balances	0.49		
Other Current financial Assets	(0.29)	-	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>			
Trade payables	(964.85)	(2,984.11)	
Borrowings			
Other current financial liabilities			
Other current liabilities			
Current tax liabilities, net	35.16	0.19	
Provisions	-597.60	518.16	
Deferred tax on amalgamation		(9)	
Cash generated from operations	208.64		260.28
Net income tax paid	(47.07)		(11.91)
Net cash flow from operating activities (A)	161.57		248.37
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-367.40	(84.82)	
Proceeds from maturity of fixed deposits			
- Others	0.81	0.80	
Net cash (used in) / flow from investing activities (B)	(366.59)		(84.02)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issue of equity shares	-	88.20	
Finance costs	-124.53	(144.60)	
Repayment of Borrowings	-27.42	18.75	
Repayment of short term Borrowings	367.92	(44.57)	
Govt Grants	-8.61	(8.61)	
Other equity Adjustment	-	(88.20)	
Net cash flow (used in) financing activities (C)	207.36		(179.04)
Net (decrease) in Cash and cash equivalents (A+B+C)	2.34		(14.68)
Cash and cash equivalents at the beginning of the year	1.21		15.89
Effect of exchange differences on translation of foreign currency Cash and cash equivalents			
Cash and cash equivalents at the end of the year (Refer Note (i) below)	3.55		1.21
* Comprises:			
Balances with Banks	0.08		0.08
Others	3.46		1.13
	3.55		1.21

As per our report of even date

For N G Rao & Associates
Chartered Accountants
Firm Registration No.:0093995

SD/-
G. Nageswara Rao
Partner
Mno-207300

Place: Hyderabad
Date: 28.06.2021



For and on behalf of the Board of Directors of
Concord Drugs Limited
CIN: L24230TG1995PLC020093

S. Nagi Reddy
S. Nagi Reddy
Managing Director
DIN:01764665

S. Koni Reddy
Koni Reddy Seelam
Executive Director
DIN: 02829319



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Date: 28.06.2021

Dear Sir,


Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, S. Nagi Reddy, Chairman & Whole time Director of Concord Drugs Limited hereby declare that the statutory Auditors of the company, M/s. N.G Rao & Associates, Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2021.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours sincerely,
For Concord Drugs Limited



S. Nagi Reddy
Chairman & Whole time Director
DIN: 01764665





INDEPENDENT AUDITOR'S REPORT ON AUDIT OF STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CONCORD DRUGS LIMITED,

1. We have audited the accompanying statement of Standalone financial results of Concord Drugs Limited ('the company'), for the three months and year ended March 31,2021('the Statement'), being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulations").
2. This statement is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act') as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the listing Regulations.Our responsibility is to express anopinion on the Statement based on our audit of such interim consolidated financial statement.
3. We conducted our audit of the Statement in accordance with the Standards on Auditing (SAs) issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the company's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal financial controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.



We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the statement
- a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - b. gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34") prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2021.

For N.G Rao and Associates
Chartered Accountants
FRN:009399S


G Nageswara Rao
(Partner)

MNo:207300

UDINNo: 21207300AAABHQ8145



Place:Hyderabad

Date:28-06-2021.